4.7 Review

Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease

Related references

Note: Only part of the references are listed.
Review Pharmacology & Pharmacy

Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting

Hui Lin et al.

Summary: The concept of local formation of angiotensin II in the kidney has evolved over the years, and this review provides a comprehensive view on how kidney angiotensin formation occurs and how it is affected by drugs. Understanding the renal renin-angiotensin system is crucial in the treatment of cardiovascular diseases and renal protection.

PHARMACOLOGICAL REVIEWS (2022)

Article Cardiac & Cardiovascular Systems

Conventional Vasopressor and Vasopressor-Sparing Strategies to Counteract the Blood Pressure-Lowering Effect of Small Interfering RNA Targeting Angiotensinogen

Estrellita Uijl et al.

Summary: The study found that conventional vasopressors can raise arterial pressure after depletion of liver angiotensinogen by siRNA, providing potential pharmacological means to regulate the blood pressure-lowering effect of angiotensinogen siRNA for future therapeutic implementation.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Article Cardiac & Cardiovascular Systems

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Ulf Landmesser et al.

Summary: The pre-specified safety analysis from ORION-1 for the siRNA therapeutic inclisiran showed no adverse effects on measures of inflammation or immune activation, nor adverse effects on platelets or clinical immunogenicity AEs over at least 6-month treatment, providing strong reassurance about the safety of inclisiran and the potential of cardiovascular RNA-targeted therapies.

CARDIOVASCULAR RESEARCH (2021)

Review Hematology

N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases

Erik A. L. Biessen et al.

Summary: The introduction of N-acetylgalactosamine technology has revolutionized oligonucleotide therapeutics, allowing safe and effective intervention in hepatic targets and even targets previously considered undruggable. This technology has been approved for multiple indications or progressed to clinical trial stages, indicating significant future potential for receptor targeted delivery of gene medicines.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Review Medical Laboratory Technology

Inflammation in Atherosclerosis-No Longer a Theory

Peter Libby

Summary: Inflammation is closely linked to atherosclerosis, and recent clinical trials have shown the effectiveness of anti-inflammatory interventions in improving outcomes for patients with the disease. Further research is needed to optimize these interventions and improve patient selection.

CLINICAL CHEMISTRY (2021)

Article Medicine, Research & Experimental

No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension

Estrellita Uijl et al.

Summary: The study found that brain angiotensin II depends on circulating angiotensinogen in DOCA-salt hypertension model. Spironolactone normalized blood pressure, restored brain angiotensin II, and lowered blood pressure, indicating that DOCA-salt hypertension is not mediated by brain RAS activation.

CLINICAL SCIENCE (2021)

Article Critical Care Medicine

Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial*

Julien Demiselle et al.

Summary: The SEPSISPAM trial found that targeting high mean arterial pressure may reduce acute kidney injury in septic shock patients with chronic hypertension, and post hoc analysis showed that chronic hypertensive patients treated with angiotensin II receptor blocker might benefit from a high mean arterial pressure target to reduce the risk of acute kidney injury.

CRITICAL CARE MEDICINE (2021)

Article Peripheral Vascular Disease

Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease

Dominique M. Bovee et al.

Summary: AGT siRNA demonstrates blood pressure-lowering and renal protective effects in hypertensive chronic kidney disease, independently of blood pressure, mainly through suppression of renal Ang II formation from liver-derived AGT.

HYPERTENSION (2021)

Letter Hematology

Renal Angiotensinogen Is Predominantly Liver Derived in Nonhuman Primates

Masayoshi Kukida et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Article Cardiac & Cardiovascular Systems

Loss of Hepatic Angiotensinogen Attenuates Sepsis-Induced Myocardial Dysfunction

Jiabing Rong et al.

Summary: The study aimed to determine the role of AGT in SIMD and investigate the underlying mechanisms. Results showed that hepatocyte-derived AGT promoted SIMD through both Ang II-dependent and Ang II-independent pathways. This study identified a liver-heart axis by which AGT regulated the development of SIMD, potentially providing a novel therapeutic target.

CIRCULATION RESEARCH (2021)

Article Peripheral Vascular Disease

CRISPR/Cas9 Mediated Deletion of the Angiotensinogen Gene Reduces Hypertension A Potential for Cure?

Hualing Sun et al.

Summary: Targeting the CRISPR/Cas9 system to hepatic AGT results in sustained reduction of blood pressure, with potential preventative effects on hypertension development in adult animals and young SHR rats. The partial disruption of the hepatic AGT gene is sufficient to control hypertension and does not affect cardiovascular stress responses.

HYPERTENSION (2021)

Article Cardiac & Cardiovascular Systems

Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx

Erin S. Morgan et al.

Summary: Targeting angiotensinogen (AGT) with IONIS-AGT-L-Rx significantly reduces AGT levels and demonstrates favorable safety and tolerability in clinical trials. Potential blood pressure reduction effects were observed, although not specifically studied for this endpoint.

JACC-BASIC TO TRANSLATIONAL SCIENCE (2021)

Article Biochemistry & Molecular Biology

Investigating the pharmacodynamic durability o f GalNAc-siRNA conjugates

Christopher R. Brown et al.

NUCLEIC ACIDS RESEARCH (2020)

Review Physiology

Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms

Dominique M. Bovee et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)

Article Peripheral Vascular Disease

Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen

Estrellita Uijl et al.

HYPERTENSION (2019)

Article Biochemistry & Molecular Biology

Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis[S]

Xin-Ran Tao et al.

JOURNAL OF LIPID RESEARCH (2019)

Article Hematology

Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report

Feiming Ye et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)

Editorial Material Hematology

Renin-Angiotensin System and Cardiovascular Functions

Chia-Hua Wu et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)

Review Cell Biology

RNA-Targeted Therapeutics

Stanley T. Crooke et al.

CELL METABOLISM (2018)

Article Biotechnology & Applied Microbiology

Reversal of siRNA - mediated gene silencing in vivo

Ivan Zlatev et al.

NATURE BIOTECHNOLOGY (2018)

Review Biochemistry & Molecular Biology

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

Aaron D. Springer et al.

NUCLEIC ACID THERAPEUTICS (2018)

Article Peripheral Vascular Disease

Brain Renin-Angiotensin System Does It Exist?

Bibi S. van Thiel et al.

HYPERTENSION (2017)

Article Medicine, General & Internal

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Kausik K. Ray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Hematology

Angiotensinogen Exerts Effects Independent of Angiotensin II

Hong Lu et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)

Article Biochemistry & Molecular Biology

Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model

Takamitsu Saigusa et al.

FASEB JOURNAL (2016)

Article Peripheral Vascular Disease

On the Origin of Urinary Renin A Translational Approach

Lodi C. W. Roksnoer et al.

HYPERTENSION (2016)

Article Peripheral Vascular Disease

Adipocytes do not significantly contribute to plasma angiotensinogen

Masahiro Koizumi et al.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2016)

Article Peripheral Vascular Disease

Deficiency of Angiotensinogen in Hepatocytes Markedly Decreases Blood Pressure in Lean and Obese Male Mice

Frederique Yiannikouris et al.

HYPERTENSION (2015)

Article Urology & Nephrology

A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression

Wei Cao et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)

Article Urology & Nephrology

New data do not SUPPORT triple RAAS blockade

A. H. Jan Danser et al.

Nature Reviews Nephrology (2015)

Article Physiology

Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2

Kameswaran Ravichandran et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)

Article Urology & Nephrology

Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II

Taiji Matsusaka et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)

Article Gastroenterology & Hepatology

The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort

Barham K. Abu Dayyeh et al.

DIGESTIVE DISEASES AND SCIENCES (2011)

Article Transplantation

Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy

Akira Nishiyama et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)

Article Cardiac & Cardiovascular Systems

Cardiac phenotype and angiotensin II levels in AT(1a), AT(1b), and AT(2) receptor single, double, and triple knockouts

Joep H. M. van Esch et al.

CARDIOVASCULAR RESEARCH (2010)

Article Multidisciplinary Sciences

A redox switch in angiotensinogen modulates angiotensin release

Aiwu Zhou et al.

NATURE (2010)

Article Gastroenterology & Hepatology

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

Eugen Florin Georgescu et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2009)

Article Medicine, General & Internal

Telmisartan, ramipril, or both in patients at high risk for vascular events

Salim Yusuf et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Multidisciplinary Sciences

Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance

Anura P. Jayasooriya et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Physiology

Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice

Romer A. Gonzalez-Villalobos et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)

Article Physiology

Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice

Hiroyuki Kobori et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)

Article Peripheral Vascular Disease

Cardiovascular and renal phenotype in mice with one or two renin genes

C Lum et al.

HYPERTENSION (2004)

Article Urology & Nephrology

Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production

H Kobori et al.

KIDNEY INTERNATIONAL (2002)

Article Pharmacology & Pharmacy

Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases

AHJ Danser et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2000)

Article Peripheral Vascular Disease

Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension

LG Navar et al.

HYPERTENSION RESEARCH (2000)